Sleep

Latest News


CME Content


Prior to the launch of solriamfetol (Sunosi) for narcolepsy and obstructive sleep apnea, the Drug Enforcement Administration designated it as a Schedule IV drug, indicating that it has a low potential for abuse and a low risk of dependence. Around the same time, results from the phase 3 TONES 3 study were published, showing the drug’s efficacy in increasing wakefulness and reducing sleepiness.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo